Jacek Capala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jacek Capala has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Gabriela Kramer-Marek
Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK
8 shared publications C. Norman Coleman
Radiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
4 shared publicationsBhadrasain Vikram
Radiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
3 shared publicationsDeepa Narayanan
Small Business Innovation Research Development Center, National Cancer Institute, Bethesda, USA
3 shared publicationsIlya Lyakhov
Protein Chemistry Laboratory, SAIC-Frederick, Inc., NCI-Frederick, Frederick, MD
3 shared publicationsOleg Chertov
Protein Chemistry Laboratory, SAIC‐Frederick, Inc. NCI‐Frederick, Frederick, Maryland 21702 (USA)
3 shared publications
Latest Publications
- 5 April 2023
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 38 (3) , 141-142
Neutron Capture Therapy: The Promise of Novel Agents and Medical Facility-Based Neutron Sources
Cancer Biotherapy & Radiopharmaceuticals
- 5 April 2023
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 38 (3) , 141-142
Neutron Capture Therapy: The Promise of Novel Agents and Medical Facility-Based Neutron Sources
Cancer Biotherapy & Radiopharmaceuticals
- 11 August 2021
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 49 (1) , 64-72
National Cancer Institute support for targeted alpha-emitter therapy
Background Radiopharmaceutical targeted therapy (RPT) has been studied for decades; however, recent clinical trials demonstrating efficacy have helped renewed interest in the modality. Methods This article reviews National Cancer Institute (NCI)’s support of RPT through communication via workshops and interest groups, through funding extramural programs in academia and small business, and through intramural research, including preclinical and clinical studies. Results NCI has co-organized workshops and organized interest groups on RPT and RPT dosimetry to encourage the community and facilitate rigorous preclinical and clinical studies. NCI has been supporting RPT research through various mechanisms. Research has been funded through peer-reviewed NCI Research and Program Grants (RPG) and NCI Small Business Innovation Research (SBIR) Development Center, which funds small business-initiated projects, some of which have led to clinical trials. The NCI Cancer Therapy Evaluation Program (CTEP)’s Radiopharmaceutical Development Initiative supports RPT in NCI-funded clinical trials, including Imaging and Radiation Oncology Core (IROC) expertise in imaging QA and dosimetry procedures. Preclinical targeted a-emitter therapy (TAT) research at the NCI’s intramural program is ongoing, building on foundational work dating back to the 1980s. Ongoing “bench-to-bedside” efforts leverage the unique infrastructure of the National Institutes of Health’s (NIH) Clinical Center. Conclusion Given the great potential of RPT, our goal is to continue to encourage its development that will generate the high-quality evidence needed to bring this multidisciplinary treatment to patients.
- 11 August 2021
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 49 (1) , 64-72
National Cancer Institute support for targeted alpha-emitter therapy
Background Radiopharmaceutical targeted therapy (RPT) has been studied for decades; however, recent clinical trials demonstrating efficacy have helped renewed interest in the modality. Methods This article reviews National Cancer Institute (NCI)’s support of RPT through communication via workshops and interest groups, through funding extramural programs in academia and small business, and through intramural research, including preclinical and clinical studies. Results NCI has co-organized workshops and organized interest groups on RPT and RPT dosimetry to encourage the community and facilitate rigorous preclinical and clinical studies. NCI has been supporting RPT research through various mechanisms. Research has been funded through peer-reviewed NCI Research and Program Grants (RPG) and NCI Small Business Innovation Research (SBIR) Development Center, which funds small business-initiated projects, some of which have led to clinical trials. The NCI Cancer Therapy Evaluation Program (CTEP)’s Radiopharmaceutical Development Initiative supports RPT in NCI-funded clinical trials, including Imaging and Radiation Oncology Core (IROC) expertise in imaging QA and dosimetry procedures. Preclinical targeted a-emitter therapy (TAT) research at the NCI’s intramural program is ongoing, building on foundational work dating back to the 1980s. Ongoing “bench-to-bedside” efforts leverage the unique infrastructure of the National Institutes of Health’s (NIH) Clinical Center. Conclusion Given the great potential of RPT, our goal is to continue to encourage its development that will generate the high-quality evidence needed to bring this multidisciplinary treatment to patients.
- Open Access
- 29 June 2021
- Published by Springer Nature in Research Square
National Cancer Institute Support for Targeted Alpha-Emitter Therapy
Radiopharmaceutical targeted therapy (RPT) has been studied for decades, however, recent clinical trials demonstrating efficacy has helped renew interest in the modality. Recognizing the potential, the National Cancer Institute (NCI) has co-organized workshops and organized interest groups on RPT and RPT dosimetry to encourage the community and facilitate rigorous preclinical and clinical studies. NCI has been supporting RPT research through various mechanisms. Research has been funded through peer reviewed NCI Research and Program Grants (RPG) and NCI Small Business Innovation Research (SBIR) Development Center, which funds small business-initiated projects, some of which have led to clinical trials. The NCI Cancer Therapy Evaluation Program (CTEP)’s Radiopharmaceutical Development Initiative supports RPT in NCI-funded clinical trials, including Imaging and Radiation Oncology Core (IROC) expertise in imaging QA and dosimetry procedures. Preclinical targeted a-emitter therapy (TAT) research at the NCI’s intramural program is ongoing, building on foundational work dating back to the 1980s. Ongoing “Bench-to-bedside” efforts leverage the unique infrastructure of the National Institutes of Health’s (NIH) Clinical Center. Given the great potential of RPT, our goal is to continue to encourage its development that will generate the high quality evidence needed to bring this multidisciplinary treatment to patients.
- 29 June 2021
- Published by Springer Nature in Research Square
Open AccessNational Cancer Institute Support for Targeted Alpha-Emitter Therapy
Radiopharmaceutical targeted therapy (RPT) has been studied for decades, however, recent clinical trials demonstrating efficacy has helped renew interest in the modality. Recognizing the potential, the National Cancer Institute (NCI) has co-organized workshops and organized interest groups on RPT and RPT dosimetry to encourage the community and facilitate rigorous preclinical and clinical studies. NCI has been supporting RPT research through various mechanisms. Research has been funded through peer reviewed NCI Research and Program Grants (RPG) and NCI Small Business Innovation Research (SBIR) Development Center, which funds small business-initiated projects, some of which have led to clinical trials. The NCI Cancer Therapy Evaluation Program (CTEP)’s Radiopharmaceutical Development Initiative supports RPT in NCI-funded clinical trials, including Imaging and Radiation Oncology Core (IROC) expertise in imaging QA and dosimetry procedures. Preclinical targeted a-emitter therapy (TAT) research at the NCI’s intramural program is ongoing, building on foundational work dating back to the 1980s. Ongoing “Bench-to-bedside” efforts leverage the unique infrastructure of the National Institutes of Health’s (NIH) Clinical Center. Given the great potential of RPT, our goal is to continue to encourage its development that will generate the high quality evidence needed to bring this multidisciplinary treatment to patients.
- Open Access
- 17 May 2021
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 5 (4)
Moving Forward in the Next Decade: Radiation Oncology Sciences for Patient-Centered Cancer Care
In a time of rapid advances in science and technology, the opportunities for radiation oncology are undergoing transformational change. The linkage between and understanding of the physical dose and induced biological perturbations are opening entirely new areas of application. The ability to define anatomic extent of disease and the elucidation of the biology of metastases has brought a key role for radiation oncology for treating metastatic disease. That radiation can stimulate and suppress subpopulations of the immune response makes radiation a key participant in cancer immunotherapy. Targeted radiopharmaceutical therapy delivers radiation systemically with radionuclides and carrier molecules selected for their physical, chemical, and biochemical properties. Radiation oncology usage of “big data” and machine learning and artificial intelligence adds the opportunity to markedly change the workflow for clinical practice while physically targeting and adapting radiation fields in real time. Future precision targeting requires multidimensional understanding of the imaging, underlying biology, and anatomical relationship among tissues for radiation as spatial and temporal “focused biology.” Other means of energy delivery are available as are agents that can be activated by radiation with increasing ability to target treatments. With broad applicability of radiation in cancer treatment, radiation therapy is a necessity for effective cancer care, opening a career path for global health serving the medically underserved in geographically isolated populations as a substantial societal contribution addressing health disparities. Understanding risk and mitigation of radiation injury make it an important discipline for and beyond cancer care including energy policy, space exploration, national security, and global partnerships.
- 17 May 2021
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 5 (4)
Open AccessMoving Forward in the Next Decade: Radiation Oncology Sciences for Patient-Centered Cancer Care
In a time of rapid advances in science and technology, the opportunities for radiation oncology are undergoing transformational change. The linkage between and understanding of the physical dose and induced biological perturbations are opening entirely new areas of application. The ability to define anatomic extent of disease and the elucidation of the biology of metastases has brought a key role for radiation oncology for treating metastatic disease. That radiation can stimulate and suppress subpopulations of the immune response makes radiation a key participant in cancer immunotherapy. Targeted radiopharmaceutical therapy delivers radiation systemically with radionuclides and carrier molecules selected for their physical, chemical, and biochemical properties. Radiation oncology usage of “big data” and machine learning and artificial intelligence adds the opportunity to markedly change the workflow for clinical practice while physically targeting and adapting radiation fields in real time. Future precision targeting requires multidimensional understanding of the imaging, underlying biology, and anatomical relationship among tissues for radiation as spatial and temporal “focused biology.” Other means of energy delivery are available as are agents that can be activated by radiation with increasing ability to target treatments. With broad applicability of radiation in cancer treatment, radiation therapy is a necessity for effective cancer care, opening a career path for global health serving the medically underserved in geographically isolated populations as a substantial societal contribution addressing health disparities. Understanding risk and mitigation of radiation injury make it an important discipline for and beyond cancer care including energy policy, space exploration, national security, and global partnerships.
- 15 January 2021
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (2) , 377-379
A New Generation of “Magic Bullets” for Molecular Targeting of Cancer
A two-step molecular targeting approach involving a self-assembling and disassembling (SADA) bispecific antibody platform and DOTA-radioconjugates allows tumor-specific delivery of diagnostic and therapeutic payloads. Low immunogenicity and the modular nature of SADA allow its optimization to safely and repeatedly deliver a variety of payloads to tumors expressing diverse tumor-specific antigens. See related article by Santich et al., p. 532
- 15 January 2021
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (2) , 377-379
A New Generation of “Magic Bullets” for Molecular Targeting of Cancer
A two-step molecular targeting approach involving a self-assembling and disassembling (SADA) bispecific antibody platform and DOTA-radioconjugates allows tumor-specific delivery of diagnostic and therapeutic payloads. Low immunogenicity and the modular nature of SADA allow its optimization to safely and repeatedly deliver a variety of payloads to tumors expressing diverse tumor-specific antigens. See related article by Santich et al., p. 532
- Open Access
- 30 September 2020
- Published by MDPI AG in Pharmaceuticals
- Vol. 13 (10) , 287
Radiopharmaceutical Switch Maintenance for Relapsed Ovarian Carcinoma
Switch maintenance, or using alternative therapeutic agents that were not administered during a prior course of cancer treatment, has emerged as an active clinical research and regulatory agency-approvable path in the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP) drug-development sequence. To better inform the design of therapeutic radiopharmaceutical trials, we reviewed academic scholarship discussing the clinical use of maintenance approaches to cancer treatment. Women with advanced-stage primary platinum-refractory or platinum-resistant ovarian carcinoma and their courses of treatment provide context for our discussion. Twenty-four (10%) out of 244 trials for women with ovarian carcinoma fit our search terms for maintenance trials. Five (2%) trials studied radiopharmaceuticals as switch maintenance. In our opinion, radiopharmaceutical switch maintenance merits further testing in prospective trials for women with advanced-stage primary platinum recurrent or refractory ovarian carcinoma.
- 30 September 2020
- Published by MDPI AG in Pharmaceuticals
- Vol. 13 (10) , 287
Open AccessRadiopharmaceutical Switch Maintenance for Relapsed Ovarian Carcinoma
Switch maintenance, or using alternative therapeutic agents that were not administered during a prior course of cancer treatment, has emerged as an active clinical research and regulatory agency-approvable path in the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP) drug-development sequence. To better inform the design of therapeutic radiopharmaceutical trials, we reviewed academic scholarship discussing the clinical use of maintenance approaches to cancer treatment. Women with advanced-stage primary platinum-refractory or platinum-resistant ovarian carcinoma and their courses of treatment provide context for our discussion. Twenty-four (10%) out of 244 trials for women with ovarian carcinoma fit our search terms for maintenance trials. Five (2%) trials studied radiopharmaceuticals as switch maintenance. In our opinion, radiopharmaceutical switch maintenance merits further testing in prospective trials for women with advanced-stage primary platinum recurrent or refractory ovarian carcinoma.
- Open Access
- 20 July 2018
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 60 (1) , 41-49
Advancing Targeted Radionuclide Therapy Through the National Cancer Institute’s Small Business Innovation Research Pathway
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs of the National Cancer Institute (NCI) are congressionally mandated set-aside programs that provide research funding to for-profit small businesses for the development of innovative technologies and treatments that serve the public good. These two programs have an annual budget of $159 million (in 2017) and serve as the NCI’s main engine of innovation for developing and commercializing cancer technologies. In collaboration with the NCI’s Radiation Research Program, the NCI SBIR Development Center published in 2015–2017 three separate requests for proposals from small businesses for the development of systemic targeted radionuclide therapy (TRT) technologies to treat cancer. TRT combines a cytotoxic radioactive isotope with a molecularly targeted agent to produce an anticancer therapy capable of treating local or systemic disease. This article summarizes the NCI SBIR funding solicitations for the development of TRTs and the research proposals funded through them.
- 20 July 2018
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 60 (1) , 41-49
Open AccessAdvancing Targeted Radionuclide Therapy Through the National Cancer Institute’s Small Business Innovation Research Pathway
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs of the National Cancer Institute (NCI) are congressionally mandated set-aside programs that provide research funding to for-profit small businesses for the development of innovative technologies and treatments that serve the public good. These two programs have an annual budget of $159 million (in 2017) and serve as the NCI’s main engine of innovation for developing and commercializing cancer technologies. In collaboration with the NCI’s Radiation Research Program, the NCI SBIR Development Center published in 2015–2017 three separate requests for proposals from small businesses for the development of systemic targeted radionuclide therapy (TRT) technologies to treat cancer. TRT combines a cytotoxic radioactive isotope with a molecularly targeted agent to produce an anticancer therapy capable of treating local or systemic disease. This article summarizes the NCI SBIR funding solicitations for the development of TRTs and the research proposals funded through them.
- Open Access
- 30 April 2018
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 78 (9) , 2166-2170
Workshop Report for Cancer Research: Defining the Shades of Gy: Utilizing the Biological Consequences of Radiotherapy in the Development of New Treatment Approaches—Meeting Viewpoint
The ability to physically target radiotherapy using image-guidance is continually improving with photons and particle therapy that include protons and heavier ions such as carbon. The unit of dose deposited is the gray (Gy); however, particle therapies produce different patterns of ionizations, and
- 30 April 2018
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 78 (9) , 2166-2170
Open AccessWorkshop Report for Cancer Research: Defining the Shades of Gy: Utilizing the Biological Consequences of Radiotherapy in the Development of New Treatment Approaches—Meeting Viewpoint
The ability to physically target radiotherapy using image-guidance is continually improving with photons and particle therapy that include protons and heavier ions such as carbon. The unit of dose deposited is the gray (Gy); however, particle therapies produce different patterns of ionizations, and
- 1 July 2016
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 95 (3) , 895-904
How Will Big Data Improve Clinical and Basic Research in Radiation Therapy?
- 1 July 2016
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 95 (3) , 895-904
How Will Big Data Improve Clinical and Basic Research in Radiation Therapy?
- 30 June 2016
- Published by Wiley in Medical Physics
- Vol. 43 (7) , 4461
Response to “Comment on ‘Medical use of all high activity sources should be eliminated for security concerns’ ” [Med. Phys. 42, 6773-6775 (2015)]
- 30 June 2016
- Published by Wiley in Medical Physics
- Vol. 43 (7) , 4461
Response to “Comment on ‘Medical use of all high activity sources should be eliminated for security concerns’ ” [Med. Phys. 42, 6773-6775 (2015)]